Differences Between Influenza A and Influenza B
Influenza A and B are distinct virus types that cause clinically identical illness but differ fundamentally in their classification, evolutionary speed, and pandemic potential—with influenza A subdivided into subtypes (currently H1N1 and H3N2 in humans) that evolve rapidly and can cause pandemics through antigenic shift, while influenza B has no subtypes, only two genetic lineages (Victoria and Yamagata), evolves more slowly, and cannot cause pandemics. 1, 2
Viral Classification and Structure
Influenza A viruses are categorized into subtypes based on two surface antigens: hemagglutinin (H) and neuraminidase (N), with 16 H subtypes and 9 N subtypes identified in nature, though only H1N1 and H3N2 currently circulate in humans. 1, 2
Influenza B viruses are not divided into subtypes; instead they are separated into two genetic lineages—Yamagata and Victoria—that co-circulate during most influenza seasons. 1, 2
Both influenza A (H1N1), A (H3N2), and B viruses have co-circulated globally since 1977. 1
Evolutionary Dynamics and Pandemic Potential
Influenza A undergoes antigenic drift markedly faster than influenza B due to frequent point mutations during viral replication, making it the primary driver of seasonal epidemics and necessitating annual vaccine updates. 1, 2, 3
Influenza B evolves more slowly, exhibiting a reduced rate of antigenic drift compared with influenza A. 1, 2
Only influenza A can cause pandemics through antigenic shift—major genetic reassortment between distinct viral strains, especially between human and animal (particularly avian) viruses—because influenza A has a natural reservoir in wild aquatic birds. 1, 2, 4, 5
The 2009 H1N1 pandemic exemplifies influenza A's pandemic capability, where a novel virus emerged with limited pre-existing immunity in the population. 1, 2
Influenza B has no animal reservoir and does not undergo antigenic shift, eliminating its pandemic potential. 6
Clinical Presentation
Both influenza A and B produce clinically indistinguishable illness characterized by abrupt onset of fever, myalgia, headache, severe malaise, non-productive cough, sore throat, and rhinitis. 2, 3
In pediatric patients, both virus types commonly cause otitis media, nausea, and vomiting. 2
Symptoms alone cannot reliably differentiate influenza A from B, requiring laboratory confirmation (RT-PCR or rapid antigen testing) for definitive diagnosis. 2
Transmission Characteristics
Both influenza A and B spread primarily via respiratory droplets expelled during coughing and sneezing. 2, 3
The incubation period for both viruses is 1–4 days (average ≈2 days). 2, 3
Adults are infectious from one day before symptom onset through approximately five days after onset for either virus type. 2, 3
Children may remain infectious for more than 10 days after symptom onset for both virus types. 2, 3
Temperature Sensitivity
- Influenza B viruses are more susceptible to high temperatures than influenza A viruses, showing decreased replication efficiency and reduced HA protein expression at 39°C compared to 33°C. 7
Immunity and Cross-Protection
Antibodies generated against one influenza type (A or B) provide limited or no protection against the other type because of distinct surface antigens. 1, 2, 3
Even within the same type, antibody to one antigenic variant may not protect against newly emerging variants of the same subtype or lineage. 1, 2, 3
Vaccine Considerations
Seasonal influenza vaccines must include both circulating A subtypes (H1N1 and H3N2) and at least one B lineage to provide adequate protection. 2
Historical trivalent vaccines containing only one B lineage mismatched the circulating B lineage in 5 of 10 seasons between 2001–2011, leading to the development of quadrivalent vaccines that include both B lineages. 1, 2
The Yamagata lineage has not been detected globally since 2020 and has been removed from U.S. seasonal vaccines, leaving only Victoria lineage in circulation. 2
Common Pitfalls
Do not assume milder illness based on virus type—both influenza A and B have similar pathogenic potential and can cause severe disease requiring hospitalization. 2
Do not rely on rapid antigen tests alone—these have limited sensitivity (40–70%) and negative results should not exclude influenza diagnosis when clinical suspicion is high. 8
Do not withhold antiviral treatment while awaiting subtype results—neuraminidase inhibitors (oseltamivir, zanamivir) are effective against both influenza A and B, and treatment decisions should not differ based on virus type. 2